Eradication rate of gastric H. pylori · patients with gastric Helicobacter pylori infection
Eradication therapy combined with periodontal therapy probably leads to higher eradication rate of gastric H. pylori compared with eradication therapy alone (moderate certainty).
1 finding from 1 review
Incidence of gastric cancer ‐ modified ITT analysis Histological examination · healthy asymptomatic H. pylori‐infected individuals
H. pylori eradication therapy probably leads to lower incidence of gastric cancer ‐ modified ITT analysisHistological… compared with control (moderate certainty).
1 finding from 1 review
Death from gastric cancer ‐ modified ITT analysis · healthy asymptomatic H. pylori‐infected individuals
H. pylori eradication therapy probably leads to lower death from gastric cancer ‐ modified ITT analysis compared with control (moderate certainty).
1 finding from 1 review
Death Analysis 1.1 · healthy asymptomatic H. pylori‐infected individuals
H. pylori eradication therapy showed no clear difference in death from all causes ‐ modified ITT analysis compared with control (moderate certainty).
1 finding from 1 review
Incidence of oesophageal squamous cell carcinoma ‐ modified ITT analysis · healthy asymptomatic H. pylori‐infected individuals
H. pylori eradication therapy showed no clear difference in incidence of oesophageal squamous cell carcinoma ‐ modified ITT… compared with control (moderate certainty).
1 finding from 1 review
Adverse events · healthy asymptomatic H. pylori‐infected individuals
1 finding from 1 review
Intervention not reported
H. pylori eradication therapy plus ulcer healing drug versus ulcer healing drug alone · people with Helicobacter pylori‐positive peptic ulcer
The intervention may leads to lower H. pylori eradication therapy plus ulcer healing drug versus ulcer… (low certainty).
1 finding from 1 review
Intervention not reported
H. pylori eradication therapy versus no active treatment · people with Helicobacter pylori‐positive peptic ulcer
The intervention may leads to lower H. pylori eradication therapy versus no active treatment (low certainty).
1 finding from 1 review
Intervention not reported
H. pylori eradication therapy versus ulcer healing drug alone · prevention of recurrence in people with Helicobacter pylori‐positive peptic ulcer
It is very uncertain whether the intervention changes H. pylori eradication therapy versus ulcer healing drug alone (very low certainty).
1 finding from 1 review
Intervention not reported
H. pylori eradication therapy versus no active treatment · prevention of recurrence in people with Helicobacter pylori‐positive peptic ulcer
It is very uncertain whether the intervention changes H. pylori eradication therapy versus no active treatment (very low certainty).
1 finding from 1 review
Non‐recurrence rate of gastric H. pylori · patients with gastric Helicobacter pylori infection
Eradication therapy combined with periodontal therapy may leads to higher non‐recurrence rate of gastric H. pylori compared with eradication therapy alone (low certainty).
1 finding from 1 review
H. pylori persistence, regardless of regimen and dose · patients with Helicobacter pylori infection
PPI triple therapy for 14 days probably leads to lower H. pylori persistence, regardless of regimen and dose compared with 7 days (moderate certainty).
1 finding from 1 review
H. pylori persistence, PAN subgroup · patients with Helicobacter pylori infection
PPI triple therapy for 10 days showed no clear difference in H. pylori persistence, PAN subgroup compared with 7 days (low certainty).
1 finding from 1 review
H. pylori persistence, PAQ subgroup · patients with Helicobacter pylori infection
PPI triple therapy for 10 days may leads to lower H. pylori persistence, PAQ subgroup compared with 7 days (low certainty).
1 finding from 1 review
H. pylori persistence, PANi subgroup · patients with Helicobacter pylori infection
It is very uncertain whether PPI triple therapy for 10 days changes H. pylori persistence, PANi subgroup compared with 7 days (very low certainty).
1 finding from 1 review
H. pylori persistence, regardless of regimen and dose · patients with Helicobacter pylori infection
PPI triple therapy for 14 days probably leads to lower H.pylori persistence, regardless of regimen and dose compared with 10 days (moderate certainty).
1 finding from 1 review
H. pylori persistence, PCA subgroup · patients with Helicobacter pylori infection
PPI triple therapy for 14 days probably leads to lower H.pylori persistence, PCA subgroup compared with 10 days (moderate certainty).
1 finding from 1 review
H. pylori persistence, PAN subgroup · patients with Helicobacter pylori infection
PPI triple therapy for 14 days showed no clear difference in H.pylori persistence, PAN subgroup compared with 10 days (low certainty).
1 finding from 1 review
H. pylori persistence, PCA subgroup · patients with Helicobacter pylori infection
PPI triple therapy for 14 days probably leads to lower H. pylori persistence, PCA subgroup compared with 7 days (moderate certainty).
1 finding from 1 review
H. pylori persistence, PCN subgroup · patients with Helicobacter pylori infection
PPI triple therapy for 14 days showed no clear difference in H. pylori persistence, PCN subgroup compared with 7 days (low certainty).
1 finding from 1 review